Company Overview and News


Add ALKEM
to your dashboard

Headline News

Alkem Labs Q2 net up 14% at Rs 327 cr on robust sales

2017-11-10 business-standard
Drug firm Alkem Laboratories on Friday reported a 13.63 per cent rise in consolidated net profit at Rs 327.44 crore for the quarter ended September 30 on account of robust sales. The company had posted a net profit of Rs 288.15 crore for the corresponding period of the previous fiscal, Alkem Laboratories said in a filing to BSE.

Alkem Laboratories Limited - Financial Result Updates

2017-11-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (15-0)

Alkem Laboratories Limited - Investor Presentation

2017-11-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (15-0)

Alkem Laboratories Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2017-11-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (15-0)

U.S. states allege broad generic drug price-fixing collusion

2017-11-01 in.reuters
WASHINGTON (Reuters) - A large group of U.S. states accused key players in the generic drug industry of a broad price-fixing conspiracy, moving on Tuesday to widen an earlier lawsuit to add many more drugmakers and medicines in an action that sent some company shares tumbling. (36-0)

U.S. states allege broad generic drug price-fixing collusion, triggering fall in pharmaceutical stocks

2017-11-01 japantimes.co.jp
WASHINGTON – A large group of U.S. states accused key players in the generic drug industry of a broad price-fixing conspiracy, moving on Tuesday to widen an earlier lawsuit to add many more drug makers and medicines in an action that sent some company shares tumbling. (36-0)

States move to expand generic drug price-fixing lawsuit

2017-10-31 channelnewsasia
Forty-six U.S. state attorneys general will seek to expand a lawsuit alleging price fixing of generic drugs to 18 companies and 15 medicines on Tuesday, including Novartis AG's generic unit Sandoz and India-based Sun Pharmaceutical Industries Ltd, people familiar with the matter said. (31-0)

UPDATE 2-U.S. states move to expand generic drug price-fixing lawsuit

2017-10-31 reuters
WASHINGTON (Reuters) - A large group of U.S. state attorneys general on Tuesday sought to expand a lawsuit alleging price fixing of generic drugs to 18 companies and 15 medicines on Tuesday, including Novartis AG’s (NOVN.S) generic unit Sandoz and India-based Sun Pharmaceutical Industries Ltd (SUN.NS). (31-0)

Alkem Laboratories Limited - Resignation

2017-10-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (15-0)

Market Live: Sensex, Nifty open at record high; ONGC, Bharti Infratel, SBI gainers

2017-10-30 moneycontrol
10:02 am Earnings reaction: Shares of Ramkrishna Forgings touched 52-week high of Rs 824.95, surging as much as 17 percent in morning as it has turned profitable in the quarter ended September 2017 (Q2FY18). (15-0)

Alkem Laboratories up 1% as no Form 483 issued for USA facility

2017-10-30 moneycontrol
Share price of Alkem Laboratories added 1 percent intraday Monday as no Form 483 issued for its USA facility.

Alkem Laboratories Limited - Press Release

2017-10-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (15-0)

Alkem Laboratories Limited - Press Release

2017-10-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (15-0)

Alkem Laboratories Limited - Appointment

2017-10-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (15-0)